| pubmed-article:16985978 | rdf:type | pubmed:Citation | lld:pubmed |
| pubmed-article:16985978 | lifeskim:mentions | umls-concept:C0376358 | lld:lifeskim |
| pubmed-article:16985978 | pubmed:dateCreated | 2006-9-20 | lld:pubmed |
| pubmed-article:16985978 | pubmed:abstractText | The eighth session of the 13th International Prostate Cancer Update focused on the mechanisms of androgen-independent cancer growth and on new therapeutic approaches to the treatment of androgen-independent prostate cancer. Three possible mechanisms that might account for the development of hormone resistance are reviewed here. These are: changes in antigen receptor expression, changes in androgen receptor structure, and changes in androgen receptor function. Therapeutic approaches discussed include the endothelin receptor antagonist astrasentan; PS-341, a boronic acid dipeptide that is highly selective for proteosome inhibition; the microtubule-stabilizing agent epothilone B; and exisulind, a selective apoptotic antineoplastic drug. The cooperative cancer study groups will move these treatments from their preliminary phase 1 and 2 studies to comparison against the standard of care for hormone-refractory prostate cancer. | lld:pubmed |
| pubmed-article:16985978 | pubmed:commentsCorrections | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:16985978 | pubmed:commentsCorrections | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:16985978 | pubmed:commentsCorrections | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:16985978 | pubmed:commentsCorrections | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:16985978 | pubmed:commentsCorrections | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:16985978 | pubmed:commentsCorrections | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:16985978 | pubmed:commentsCorrections | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:16985978 | pubmed:commentsCorrections | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:16985978 | pubmed:commentsCorrections | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:16985978 | pubmed:commentsCorrections | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:16985978 | pubmed:commentsCorrections | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:16985978 | pubmed:commentsCorrections | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:16985978 | pubmed:commentsCorrections | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:16985978 | pubmed:commentsCorrections | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:16985978 | pubmed:language | eng | lld:pubmed |
| pubmed-article:16985978 | pubmed:journal | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:16985978 | pubmed:status | PubMed-not-MEDLINE | lld:pubmed |
| pubmed-article:16985978 | pubmed:issn | 1523-6161 | lld:pubmed |
| pubmed-article:16985978 | pubmed:author | pubmed-author:PetrylakDanie... | lld:pubmed |
| pubmed-article:16985978 | pubmed:issnType | Print | lld:pubmed |
| pubmed-article:16985978 | pubmed:volume | 5 Suppl 6 | lld:pubmed |
| pubmed-article:16985978 | pubmed:owner | NLM | lld:pubmed |
| pubmed-article:16985978 | pubmed:authorsComplete | Y | lld:pubmed |
| pubmed-article:16985978 | pubmed:pagination | S54-8 | lld:pubmed |
| pubmed-article:16985978 | pubmed:year | 2003 | lld:pubmed |
| pubmed-article:16985978 | pubmed:articleTitle | Hormone-refractory prostate cancer: new horizons. | lld:pubmed |
| pubmed-article:16985978 | pubmed:publicationType | Journal Article | lld:pubmed |
